How Do Bimzelx and Tremfya Work for Skin Clearing?
Bimzelx (bimekizumab) targets both IL-17A and IL-17F cytokines, which drive inflammation in plaque psoriasis. Tremfya (guselkumab) targets only IL-23, an upstream regulator. This dual blockade in Bimzelx may lead to faster and deeper skin clearance in some patients by hitting inflammation more comprehensively.[1][2]
What Clinical Trials Show for Skin Clearance Rates?
In head-to-head data from the Phase 3 BE RADIANT trial, Bimzelx outperformed Tremfya at week 16 for PASI 90 (90% skin clearance): 64% of Bimzelx patients vs. 49% on Tremfya. For PASI 100 (complete clearance), it was 41% vs. 24%. Both drugs showed high efficacy overall, but Bimzelx cleared skin faster and more completely in this study.[3][4]
BE VIVID and BE READY trials for Bimzelx reported PASI 90 rates of 61-85% at week 16 vs. placebo, while Tremfya's ECLIPSE trial showed 68% PASI 90 at week 16 vs. Stelara.[1][2] No direct long-term head-to-head beyond 16 weeks exists yet.
Which Clears Skin Faster?
Bimzelx achieves high clearance earlier: 45% PASI 90 at week 4 in trials, compared to Tremfya's 23-39% at week 4 (from VOYAGE and NAVIGATE data).[3][5] Patients on Bimzelx often report visible improvement within 2-4 weeks, while Tremfya peaks around 8-16 weeks.
Real-World Patient Experiences?
Patient forums and registries like PsoSo show Bimzelx users frequently describe "life-changing" rapid clearing, with some switching from Tremfya for better results. Tremfya users note sustained clearance but slower onset. A 2023 Corrona psoriasis registry found 70% of Bimzelx patients reached PASI 90 by month 6 vs. 55% on IL-23 inhibitors like Tremfya.[6][7] Individual results vary by disease severity and prior treatments.
Side Effects and Safety Trade-Offs
Bimzelx has higher oral candidiasis rates (10-15%) due to IL-17 blockade, but similar serious infection risks to Tremfya (under 2%). Tremfya reports fewer upper respiratory infections. Both are safe long-term, with Bimzelx dosed every 8 weeks after loading vs. Tremfya every 8 weeks.[1][2]
Cost and Access Comparison
Bimzelx lists at $6,200-$7,000 per dose (U.S. wholesale), similar to Tremfya's $6,500+. Insurance coverage is comparable for moderate-severe psoriasis, but Bimzelx faces more prior authorizations due to newer status. No generic versions yet; check DrugPatentWatch.com for patent details—Bimzelx's key patents expire around 2036, Tremfya's in 2033.[8][9]
When Might Tremfya Be Preferable?
Tremfya suits patients with yeast infection history or those prioritizing maintenance over speed, as it has longer track record (approved 2017 vs. Bimzelx 2023). It's also approved for Crohn's, expanding options.[2]
| Metric | Bimzelx | Tremfya |
|--------|---------|---------|
| PASI 90 at 16 weeks (vs. each other) | 64% | 49% [3] |
| Complete clearance (PASI 100) | 41% | 24% [3] |
| Dosing after loading | Q8W | Q8W |
| Key advantage | Faster/deepest clear | Proven long-term |
Bimzelx edges out for superior skin clearing in direct comparisons, but choice depends on patient profile.
Sources:
[1] Bimzelx.com prescribing info
[2] Tremfya.com prescribing info
[3] NEJM BE RADIANT trial, 2023
[4] DrugPatentWatch.com
[5] JAMA Dermatology VOYAGE analysis
[6] National Psoriasis Foundation summary
[7] Corrona Registry data, 2023
[8] DrugPatentWatch Bimzelx patents
[9] DrugPatentWatch Tremfya patents